nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Vismodegib—skin cancer	0.126	0.25	CbGbCtD
Atomoxetine—CYP3A4—Temozolomide—skin cancer	0.0875	0.175	CbGbCtD
Atomoxetine—CYP3A4—Imiquimod—skin cancer	0.0875	0.175	CbGbCtD
Atomoxetine—CYP2D6—Vemurafenib—skin cancer	0.0754	0.151	CbGbCtD
Atomoxetine—CYP3A4—Vismodegib—skin cancer	0.0607	0.121	CbGbCtD
Atomoxetine—CYP3A4—Vemurafenib—skin cancer	0.048	0.0957	CbGbCtD
Atomoxetine—CYP3A4—Docetaxel—skin cancer	0.0165	0.0328	CbGbCtD
Atomoxetine—NPY1R—nerve—skin cancer	0.0102	0.139	CbGeAlD
Atomoxetine—NPY1R—nipple—skin cancer	0.00581	0.0788	CbGeAlD
Atomoxetine—SLC6A3—nerve—skin cancer	0.0043	0.0584	CbGeAlD
Atomoxetine—SLC6A2—nerve—skin cancer	0.00347	0.0471	CbGeAlD
Atomoxetine—HTR2A—hindlimb—skin cancer	0.00343	0.0465	CbGeAlD
Atomoxetine—HTR1B—blood vessel—skin cancer	0.00341	0.0462	CbGeAlD
Atomoxetine—NPY1R—mammalian vulva—skin cancer	0.00339	0.046	CbGeAlD
Atomoxetine—HTR1D—blood vessel—skin cancer	0.0033	0.0447	CbGeAlD
Atomoxetine—HTR2A—appendage—skin cancer	0.00294	0.0399	CbGeAlD
Atomoxetine—NPY1R—female reproductive system—skin cancer	0.0029	0.0394	CbGeAlD
Atomoxetine—NPY1R—head—skin cancer	0.00243	0.0329	CbGeAlD
Atomoxetine—HTR2A—nerve—skin cancer	0.00209	0.0283	CbGeAlD
Atomoxetine—HTR2A—endothelium—skin cancer	0.00178	0.0241	CbGeAlD
Atomoxetine—HTR6—head—skin cancer	0.00171	0.0232	CbGeAlD
Atomoxetine—NPY1R—lymph node—skin cancer	0.0017	0.023	CbGeAlD
Atomoxetine—HTR1D—connective tissue—skin cancer	0.00169	0.0229	CbGeAlD
Atomoxetine—HTR2A—blood vessel—skin cancer	0.00164	0.0222	CbGeAlD
Atomoxetine—HTR1B—female reproductive system—skin cancer	0.00123	0.0167	CbGeAlD
Atomoxetine—HTR1D—female reproductive system—skin cancer	0.00119	0.0162	CbGeAlD
Atomoxetine—HTR2C—female reproductive system—skin cancer	0.00118	0.016	CbGeAlD
Atomoxetine—HTR2A—neck—skin cancer	0.00117	0.0159	CbGeAlD
Atomoxetine—SLC6A4—female reproductive system—skin cancer	0.00112	0.0152	CbGeAlD
Atomoxetine—HTR1B—head—skin cancer	0.00103	0.014	CbGeAlD
Atomoxetine—SLC6A3—head—skin cancer	0.00102	0.0138	CbGeAlD
Atomoxetine—HTR1D—head—skin cancer	0.000997	0.0135	CbGeAlD
Atomoxetine—HTR2C—head—skin cancer	0.000987	0.0134	CbGeAlD
Atomoxetine—SLC6A2—female reproductive system—skin cancer	0.000986	0.0134	CbGeAlD
Atomoxetine—SLC6A4—head—skin cancer	0.000936	0.0127	CbGeAlD
Atomoxetine—HTR2A—connective tissue—skin cancer	0.00084	0.0114	CbGeAlD
Atomoxetine—SLC6A2—head—skin cancer	0.000824	0.0112	CbGeAlD
Atomoxetine—HTR2A—epithelium—skin cancer	0.000798	0.0108	CbGeAlD
Atomoxetine—Chest pain—Imiquimod—skin cancer	0.000772	0.00191	CcSEcCtD
Atomoxetine—Myalgia—Imiquimod—skin cancer	0.000772	0.00191	CcSEcCtD
Atomoxetine—Arthralgia—Imiquimod—skin cancer	0.000772	0.00191	CcSEcCtD
Atomoxetine—Anxiety—Imiquimod—skin cancer	0.000769	0.0019	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000766	0.0019	CcSEcCtD
Atomoxetine—Sweating increased—Temozolomide—skin cancer	0.000759	0.00188	CcSEcCtD
Atomoxetine—Dry mouth—Imiquimod—skin cancer	0.000755	0.00187	CcSEcCtD
Atomoxetine—Decreased appetite—Vemurafenib—skin cancer	0.000754	0.00187	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000749	0.00185	CcSEcCtD
Atomoxetine—Fatigue—Vemurafenib—skin cancer	0.000748	0.00185	CcSEcCtD
Atomoxetine—Nasopharyngitis—Fluorouracil—skin cancer	0.000743	0.00184	CcSEcCtD
Atomoxetine—Constipation—Vemurafenib—skin cancer	0.000742	0.00184	CcSEcCtD
Atomoxetine—Hypoaesthesia—Bleomycin—skin cancer	0.000736	0.00182	CcSEcCtD
Atomoxetine—Infection—Imiquimod—skin cancer	0.000735	0.00182	CcSEcCtD
Atomoxetine—Dysuria—Temozolomide—skin cancer	0.000729	0.00181	CcSEcCtD
Atomoxetine—Shock—Imiquimod—skin cancer	0.000728	0.0018	CcSEcCtD
Atomoxetine—Nervous system disorder—Imiquimod—skin cancer	0.000725	0.0018	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Temozolomide—skin cancer	0.000724	0.00179	CcSEcCtD
Atomoxetine—Tachycardia—Imiquimod—skin cancer	0.000722	0.00179	CcSEcCtD
Atomoxetine—Pollakiuria—Temozolomide—skin cancer	0.00072	0.00178	CcSEcCtD
Atomoxetine—Skin disorder—Imiquimod—skin cancer	0.000718	0.00178	CcSEcCtD
Atomoxetine—Erectile dysfunction—Temozolomide—skin cancer	0.000718	0.00178	CcSEcCtD
Atomoxetine—Hyperhidrosis—Imiquimod—skin cancer	0.000715	0.00177	CcSEcCtD
Atomoxetine—Weight decreased—Temozolomide—skin cancer	0.000705	0.00175	CcSEcCtD
Atomoxetine—Anorexia—Imiquimod—skin cancer	0.000705	0.00175	CcSEcCtD
Atomoxetine—Infestation—Temozolomide—skin cancer	0.000695	0.00172	CcSEcCtD
Atomoxetine—Infestation NOS—Temozolomide—skin cancer	0.000695	0.00172	CcSEcCtD
Atomoxetine—Depression—Temozolomide—skin cancer	0.000693	0.00172	CcSEcCtD
Atomoxetine—Flushing—Bleomycin—skin cancer	0.000686	0.0017	CcSEcCtD
Atomoxetine—Body temperature increased—Vemurafenib—skin cancer	0.000686	0.0017	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000674	0.00167	CcSEcCtD
Atomoxetine—Insomnia—Imiquimod—skin cancer	0.000669	0.00166	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000667	0.00165	CcSEcCtD
Atomoxetine—Hepatic failure—Docetaxel—skin cancer	0.000667	0.00165	CcSEcCtD
Atomoxetine—Paraesthesia—Imiquimod—skin cancer	0.000664	0.00164	CcSEcCtD
Atomoxetine—Chills—Bleomycin—skin cancer	0.000664	0.00164	CcSEcCtD
Atomoxetine—Somnolence—Imiquimod—skin cancer	0.000658	0.00163	CcSEcCtD
Atomoxetine—Sinusitis—Temozolomide—skin cancer	0.000652	0.00161	CcSEcCtD
Atomoxetine—Dyspepsia—Imiquimod—skin cancer	0.000651	0.00161	CcSEcCtD
Atomoxetine—Decreased appetite—Imiquimod—skin cancer	0.000643	0.00159	CcSEcCtD
Atomoxetine—Hot flush—Docetaxel—skin cancer	0.000641	0.00159	CcSEcCtD
Atomoxetine—Infestation NOS—Fluorouracil—skin cancer	0.00064	0.00159	CcSEcCtD
Atomoxetine—Infestation—Fluorouracil—skin cancer	0.00064	0.00159	CcSEcCtD
Atomoxetine—Flushing—Dactinomycin—skin cancer	0.00064	0.00159	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000639	0.00158	CcSEcCtD
Atomoxetine—Fatigue—Imiquimod—skin cancer	0.000638	0.00158	CcSEcCtD
Atomoxetine—Menopausal symptoms—Docetaxel—skin cancer	0.000636	0.00157	CcSEcCtD
Atomoxetine—Pain—Imiquimod—skin cancer	0.000633	0.00157	CcSEcCtD
Atomoxetine—Conjunctivitis—Fluorouracil—skin cancer	0.000622	0.00154	CcSEcCtD
Atomoxetine—Asthenia—Vemurafenib—skin cancer	0.000622	0.00154	CcSEcCtD
Atomoxetine—Hypoaesthesia—Temozolomide—skin cancer	0.000621	0.00154	CcSEcCtD
Atomoxetine—Hallucination—Temozolomide—skin cancer	0.000621	0.00154	CcSEcCtD
Atomoxetine—Chills—Dactinomycin—skin cancer	0.000619	0.00153	CcSEcCtD
Atomoxetine—Urinary tract disorder—Temozolomide—skin cancer	0.000616	0.00153	CcSEcCtD
Atomoxetine—Pruritus—Vemurafenib—skin cancer	0.000614	0.00152	CcSEcCtD
Atomoxetine—Lethargy—Docetaxel—skin cancer	0.000612	0.00152	CcSEcCtD
Atomoxetine—Urethral disorder—Temozolomide—skin cancer	0.000612	0.00151	CcSEcCtD
Atomoxetine—Feeling abnormal—Imiquimod—skin cancer	0.00061	0.00151	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Imiquimod—skin cancer	0.000605	0.0015	CcSEcCtD
Atomoxetine—Sinusitis—Fluorouracil—skin cancer	0.000601	0.00149	CcSEcCtD
Atomoxetine—Diarrhoea—Vemurafenib—skin cancer	0.000593	0.00147	CcSEcCtD
Atomoxetine—HTR2A—female reproductive system—skin cancer	0.000593	0.00804	CbGeAlD
Atomoxetine—Urticaria—Imiquimod—skin cancer	0.000588	0.00146	CcSEcCtD
Atomoxetine—Abdominal pain—Imiquimod—skin cancer	0.000585	0.00145	CcSEcCtD
Atomoxetine—Body temperature increased—Imiquimod—skin cancer	0.000585	0.00145	CcSEcCtD
Atomoxetine—Flushing—Temozolomide—skin cancer	0.000579	0.00143	CcSEcCtD
Atomoxetine—Cardiac disorder—Temozolomide—skin cancer	0.000579	0.00143	CcSEcCtD
Atomoxetine—SLC6A2—lymph node—skin cancer	0.000577	0.00782	CbGeAlD
Atomoxetine—Dizziness—Vemurafenib—skin cancer	0.000574	0.00142	CcSEcCtD
Atomoxetine—Hypoaesthesia—Fluorouracil—skin cancer	0.000572	0.00142	CcSEcCtD
Atomoxetine—Angiopathy—Temozolomide—skin cancer	0.000566	0.0014	CcSEcCtD
Atomoxetine—Mediastinal disorder—Temozolomide—skin cancer	0.000562	0.00139	CcSEcCtD
Atomoxetine—Cough—Bleomycin—skin cancer	0.000562	0.00139	CcSEcCtD
Atomoxetine—Chills—Temozolomide—skin cancer	0.00056	0.00139	CcSEcCtD
Atomoxetine—Vomiting—Vemurafenib—skin cancer	0.000551	0.00137	CcSEcCtD
Atomoxetine—CYP3A4—female reproductive system—skin cancer	0.000549	0.00744	CbGeAlD
Atomoxetine—Chest pain—Bleomycin—skin cancer	0.000548	0.00136	CcSEcCtD
Atomoxetine—Myalgia—Bleomycin—skin cancer	0.000548	0.00136	CcSEcCtD
Atomoxetine—Abdominal pain upper—Docetaxel—skin cancer	0.000548	0.00136	CcSEcCtD
Atomoxetine—Rash—Vemurafenib—skin cancer	0.000547	0.00135	CcSEcCtD
Atomoxetine—Mental disorder—Temozolomide—skin cancer	0.000547	0.00135	CcSEcCtD
Atomoxetine—Dermatitis—Vemurafenib—skin cancer	0.000546	0.00135	CcSEcCtD
Atomoxetine—Headache—Vemurafenib—skin cancer	0.000543	0.00135	CcSEcCtD
Atomoxetine—Malnutrition—Temozolomide—skin cancer	0.000543	0.00135	CcSEcCtD
Atomoxetine—Breast disorder—Docetaxel—skin cancer	0.000542	0.00134	CcSEcCtD
Atomoxetine—CYP2D6—female reproductive system—skin cancer	0.00054	0.00732	CbGeAlD
Atomoxetine—Nasopharyngitis—Docetaxel—skin cancer	0.000536	0.00133	CcSEcCtD
Atomoxetine—Dysgeusia—Temozolomide—skin cancer	0.000532	0.00132	CcSEcCtD
Atomoxetine—Asthenia—Imiquimod—skin cancer	0.000531	0.00131	CcSEcCtD
Atomoxetine—Back pain—Temozolomide—skin cancer	0.000525	0.0013	CcSEcCtD
Atomoxetine—Pruritus—Imiquimod—skin cancer	0.000523	0.0013	CcSEcCtD
Atomoxetine—Infection—Bleomycin—skin cancer	0.000522	0.00129	CcSEcCtD
Atomoxetine—Nausea—Vemurafenib—skin cancer	0.000515	0.00128	CcSEcCtD
Atomoxetine—Vision blurred—Temozolomide—skin cancer	0.000512	0.00127	CcSEcCtD
Atomoxetine—Myalgia—Dactinomycin—skin cancer	0.000511	0.00127	CcSEcCtD
Atomoxetine—Tremor—Temozolomide—skin cancer	0.000509	0.00126	CcSEcCtD
Atomoxetine—Diarrhoea—Imiquimod—skin cancer	0.000506	0.00125	CcSEcCtD
Atomoxetine—Anorexia—Bleomycin—skin cancer	0.000501	0.00124	CcSEcCtD
Atomoxetine—Agitation—Temozolomide—skin cancer	0.000499	0.00124	CcSEcCtD
Atomoxetine—HTR2A—head—skin cancer	0.000495	0.00671	CbGeAlD
Atomoxetine—Dizziness—Imiquimod—skin cancer	0.000489	0.00121	CcSEcCtD
Atomoxetine—Vertigo—Temozolomide—skin cancer	0.000488	0.00121	CcSEcCtD
Atomoxetine—Infection—Dactinomycin—skin cancer	0.000487	0.00121	CcSEcCtD
Atomoxetine—Palpitations—Temozolomide—skin cancer	0.00048	0.00119	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000479	0.00119	CcSEcCtD
Atomoxetine—Cough—Temozolomide—skin cancer	0.000474	0.00117	CcSEcCtD
Atomoxetine—Paraesthesia—Bleomycin—skin cancer	0.000472	0.00117	CcSEcCtD
Atomoxetine—Vision blurred—Fluorouracil—skin cancer	0.000472	0.00117	CcSEcCtD
Atomoxetine—Convulsion—Temozolomide—skin cancer	0.000471	0.00117	CcSEcCtD
Atomoxetine—Vomiting—Imiquimod—skin cancer	0.00047	0.00116	CcSEcCtD
Atomoxetine—Weight decreased—Docetaxel—skin cancer	0.000469	0.00116	CcSEcCtD
Atomoxetine—Anorexia—Dactinomycin—skin cancer	0.000467	0.00116	CcSEcCtD
Atomoxetine—Rash—Imiquimod—skin cancer	0.000466	0.00116	CcSEcCtD
Atomoxetine—Dermatitis—Imiquimod—skin cancer	0.000466	0.00115	CcSEcCtD
Atomoxetine—Headache—Imiquimod—skin cancer	0.000463	0.00115	CcSEcCtD
Atomoxetine—Arthralgia—Temozolomide—skin cancer	0.000462	0.00115	CcSEcCtD
Atomoxetine—Myalgia—Temozolomide—skin cancer	0.000462	0.00115	CcSEcCtD
Atomoxetine—Infestation NOS—Docetaxel—skin cancer	0.000462	0.00114	CcSEcCtD
Atomoxetine—Infestation—Docetaxel—skin cancer	0.000462	0.00114	CcSEcCtD
Atomoxetine—Anxiety—Temozolomide—skin cancer	0.000461	0.00114	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000459	0.00114	CcSEcCtD
Atomoxetine—Decreased appetite—Bleomycin—skin cancer	0.000457	0.00113	CcSEcCtD
Atomoxetine—Dry mouth—Temozolomide—skin cancer	0.000452	0.00112	CcSEcCtD
Atomoxetine—CYP2D6—head—skin cancer	0.000451	0.00612	CbGeAlD
Atomoxetine—Pain—Bleomycin—skin cancer	0.000449	0.00111	CcSEcCtD
Atomoxetine—Conjunctivitis—Docetaxel—skin cancer	0.000449	0.00111	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000446	0.00111	CcSEcCtD
Atomoxetine—Infection—Temozolomide—skin cancer	0.00044	0.00109	CcSEcCtD
Atomoxetine—Nausea—Imiquimod—skin cancer	0.000439	0.00109	CcSEcCtD
Atomoxetine—Nervous system disorder—Temozolomide—skin cancer	0.000435	0.00108	CcSEcCtD
Atomoxetine—Convulsion—Fluorouracil—skin cancer	0.000434	0.00107	CcSEcCtD
Atomoxetine—Feeling abnormal—Bleomycin—skin cancer	0.000433	0.00107	CcSEcCtD
Atomoxetine—Skin disorder—Temozolomide—skin cancer	0.000431	0.00107	CcSEcCtD
Atomoxetine—Hyperhidrosis—Temozolomide—skin cancer	0.000429	0.00106	CcSEcCtD
Atomoxetine—Myalgia—Fluorouracil—skin cancer	0.000426	0.00106	CcSEcCtD
Atomoxetine—Chest pain—Fluorouracil—skin cancer	0.000426	0.00106	CcSEcCtD
Atomoxetine—Decreased appetite—Dactinomycin—skin cancer	0.000426	0.00106	CcSEcCtD
Atomoxetine—Fatigue—Dactinomycin—skin cancer	0.000423	0.00105	CcSEcCtD
Atomoxetine—Anorexia—Temozolomide—skin cancer	0.000423	0.00105	CcSEcCtD
Atomoxetine—Pain—Dactinomycin—skin cancer	0.000419	0.00104	CcSEcCtD
Atomoxetine—Urticaria—Bleomycin—skin cancer	0.000417	0.00103	CcSEcCtD
Atomoxetine—Body temperature increased—Bleomycin—skin cancer	0.000415	0.00103	CcSEcCtD
Atomoxetine—Hypoaesthesia—Docetaxel—skin cancer	0.000413	0.00102	CcSEcCtD
Atomoxetine—Urinary tract disorder—Docetaxel—skin cancer	0.00041	0.00101	CcSEcCtD
Atomoxetine—Urethral disorder—Docetaxel—skin cancer	0.000407	0.00101	CcSEcCtD
Atomoxetine—Infection—Fluorouracil—skin cancer	0.000406	0.001	CcSEcCtD
Atomoxetine—Feeling abnormal—Dactinomycin—skin cancer	0.000404	0.001	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000404	0.001	CcSEcCtD
Atomoxetine—Insomnia—Temozolomide—skin cancer	0.000401	0.000993	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000401	0.000993	CcSEcCtD
Atomoxetine—Nervous system disorder—Fluorouracil—skin cancer	0.000401	0.000992	CcSEcCtD
Atomoxetine—Orphenadrine—SCN10A—skin cancer	0.000399	0.501	CrCbGaD
Atomoxetine—Tachycardia—Fluorouracil—skin cancer	0.000399	0.000987	CcSEcCtD
Atomoxetine—Paraesthesia—Temozolomide—skin cancer	0.000398	0.000986	CcSEcCtD
Atomoxetine—Somnolence—Temozolomide—skin cancer	0.000394	0.000976	CcSEcCtD
Atomoxetine—Dyspepsia—Temozolomide—skin cancer	0.00039	0.000966	CcSEcCtD
Atomoxetine—Anorexia—Fluorouracil—skin cancer	0.000389	0.000964	CcSEcCtD
Atomoxetine—Abdominal pain—Dactinomycin—skin cancer	0.000387	0.00096	CcSEcCtD
Atomoxetine—Body temperature increased—Dactinomycin—skin cancer	0.000387	0.00096	CcSEcCtD
Atomoxetine—Decreased appetite—Temozolomide—skin cancer	0.000385	0.000954	CcSEcCtD
Atomoxetine—Cardiac disorder—Docetaxel—skin cancer	0.000385	0.000954	CcSEcCtD
Atomoxetine—Flushing—Docetaxel—skin cancer	0.000385	0.000954	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000383	0.000948	CcSEcCtD
Atomoxetine—Fatigue—Temozolomide—skin cancer	0.000382	0.000946	CcSEcCtD
Atomoxetine—Constipation—Temozolomide—skin cancer	0.000379	0.000939	CcSEcCtD
Atomoxetine—Pain—Temozolomide—skin cancer	0.000379	0.000939	CcSEcCtD
Atomoxetine—Asthenia—Bleomycin—skin cancer	0.000377	0.000934	CcSEcCtD
Atomoxetine—Angiopathy—Docetaxel—skin cancer	0.000376	0.000932	CcSEcCtD
Atomoxetine—Mediastinal disorder—Docetaxel—skin cancer	0.000374	0.000926	CcSEcCtD
Atomoxetine—Chills—Docetaxel—skin cancer	0.000372	0.000922	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000372	0.000922	CcSEcCtD
Atomoxetine—Pruritus—Bleomycin—skin cancer	0.000372	0.000921	CcSEcCtD
Atomoxetine—Insomnia—Fluorouracil—skin cancer	0.000369	0.000915	CcSEcCtD
Atomoxetine—Paraesthesia—Fluorouracil—skin cancer	0.000367	0.000908	CcSEcCtD
Atomoxetine—Feeling abnormal—Temozolomide—skin cancer	0.000365	0.000905	CcSEcCtD
Atomoxetine—Mental disorder—Docetaxel—skin cancer	0.000363	0.0009	CcSEcCtD
Atomoxetine—Somnolence—Fluorouracil—skin cancer	0.000363	0.000899	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Temozolomide—skin cancer	0.000362	0.000898	CcSEcCtD
Atomoxetine—Malnutrition—Docetaxel—skin cancer	0.000361	0.000895	CcSEcCtD
Atomoxetine—Dyspepsia—Fluorouracil—skin cancer	0.000359	0.00089	CcSEcCtD
Atomoxetine—Decreased appetite—Fluorouracil—skin cancer	0.000355	0.000879	CcSEcCtD
Atomoxetine—Dysgeusia—Docetaxel—skin cancer	0.000354	0.000876	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000353	0.000873	CcSEcCtD
Atomoxetine—Urticaria—Temozolomide—skin cancer	0.000352	0.000872	CcSEcCtD
Atomoxetine—Asthenia—Dactinomycin—skin cancer	0.000352	0.000871	CcSEcCtD
Atomoxetine—Abdominal pain—Temozolomide—skin cancer	0.00035	0.000868	CcSEcCtD
Atomoxetine—Body temperature increased—Temozolomide—skin cancer	0.00035	0.000868	CcSEcCtD
Atomoxetine—Back pain—Docetaxel—skin cancer	0.000349	0.000865	CcSEcCtD
Atomoxetine—Pain—Fluorouracil—skin cancer	0.000349	0.000865	CcSEcCtD
Atomoxetine—Muscle spasms—Docetaxel—skin cancer	0.000347	0.00086	CcSEcCtD
Atomoxetine—Feeling abnormal—Fluorouracil—skin cancer	0.000337	0.000834	CcSEcCtD
Atomoxetine—Diarrhoea—Dactinomycin—skin cancer	0.000335	0.00083	CcSEcCtD
Atomoxetine—Vomiting—Bleomycin—skin cancer	0.000334	0.000827	CcSEcCtD
Atomoxetine—Rash—Bleomycin—skin cancer	0.000331	0.000821	CcSEcCtD
Atomoxetine—Dermatitis—Bleomycin—skin cancer	0.000331	0.00082	CcSEcCtD
Atomoxetine—Urticaria—Fluorouracil—skin cancer	0.000324	0.000804	CcSEcCtD
Atomoxetine—Syncope—Docetaxel—skin cancer	0.000324	0.000802	CcSEcCtD
Atomoxetine—Body temperature increased—Fluorouracil—skin cancer	0.000323	0.0008	CcSEcCtD
Atomoxetine—Palpitations—Docetaxel—skin cancer	0.000319	0.000791	CcSEcCtD
Atomoxetine—Asthenia—Temozolomide—skin cancer	0.000318	0.000788	CcSEcCtD
Atomoxetine—Loss of consciousness—Docetaxel—skin cancer	0.000317	0.000786	CcSEcCtD
Atomoxetine—Cough—Docetaxel—skin cancer	0.000315	0.000781	CcSEcCtD
Atomoxetine—Pruritus—Temozolomide—skin cancer	0.000314	0.000777	CcSEcCtD
Atomoxetine—Convulsion—Docetaxel—skin cancer	0.000313	0.000775	CcSEcCtD
Atomoxetine—Nausea—Bleomycin—skin cancer	0.000312	0.000773	CcSEcCtD
Atomoxetine—Vomiting—Dactinomycin—skin cancer	0.000312	0.000772	CcSEcCtD
Atomoxetine—Rash—Dactinomycin—skin cancer	0.000309	0.000765	CcSEcCtD
Atomoxetine—Myalgia—Docetaxel—skin cancer	0.000307	0.000762	CcSEcCtD
Atomoxetine—Arthralgia—Docetaxel—skin cancer	0.000307	0.000762	CcSEcCtD
Atomoxetine—Chest pain—Docetaxel—skin cancer	0.000307	0.000762	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000305	0.000756	CcSEcCtD
Atomoxetine—Diarrhoea—Temozolomide—skin cancer	0.000303	0.000751	CcSEcCtD
Atomoxetine—Dry mouth—Docetaxel—skin cancer	0.000301	0.000745	CcSEcCtD
Atomoxetine—Dizziness—Temozolomide—skin cancer	0.000293	0.000726	CcSEcCtD
Atomoxetine—Infection—Docetaxel—skin cancer	0.000293	0.000725	CcSEcCtD
Atomoxetine—Nausea—Dactinomycin—skin cancer	0.000291	0.000721	CcSEcCtD
Atomoxetine—Shock—Docetaxel—skin cancer	0.00029	0.000718	CcSEcCtD
Atomoxetine—Nervous system disorder—Docetaxel—skin cancer	0.000289	0.000716	CcSEcCtD
Atomoxetine—Pruritus—Fluorouracil—skin cancer	0.000289	0.000716	CcSEcCtD
Atomoxetine—Tachycardia—Docetaxel—skin cancer	0.000288	0.000713	CcSEcCtD
Atomoxetine—Skin disorder—Docetaxel—skin cancer	0.000286	0.000709	CcSEcCtD
Atomoxetine—Vomiting—Temozolomide—skin cancer	0.000282	0.000698	CcSEcCtD
Atomoxetine—Anorexia—Docetaxel—skin cancer	0.000281	0.000696	CcSEcCtD
Atomoxetine—Rash—Temozolomide—skin cancer	0.000279	0.000692	CcSEcCtD
Atomoxetine—Diarrhoea—Fluorouracil—skin cancer	0.000279	0.000692	CcSEcCtD
Atomoxetine—Dermatitis—Temozolomide—skin cancer	0.000279	0.000692	CcSEcCtD
Atomoxetine—Headache—Temozolomide—skin cancer	0.000278	0.000688	CcSEcCtD
Atomoxetine—Dizziness—Fluorouracil—skin cancer	0.00027	0.000669	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000269	0.000665	CcSEcCtD
Atomoxetine—Insomnia—Docetaxel—skin cancer	0.000267	0.00066	CcSEcCtD
Atomoxetine—Paraesthesia—Docetaxel—skin cancer	0.000265	0.000656	CcSEcCtD
Atomoxetine—Nausea—Temozolomide—skin cancer	0.000263	0.000652	CcSEcCtD
Atomoxetine—Somnolence—Docetaxel—skin cancer	0.000262	0.000649	CcSEcCtD
Atomoxetine—Vomiting—Fluorouracil—skin cancer	0.00026	0.000643	CcSEcCtD
Atomoxetine—Dyspepsia—Docetaxel—skin cancer	0.000259	0.000643	CcSEcCtD
Atomoxetine—Rash—Fluorouracil—skin cancer	0.000258	0.000638	CcSEcCtD
Atomoxetine—Dermatitis—Fluorouracil—skin cancer	0.000257	0.000637	CcSEcCtD
Atomoxetine—Decreased appetite—Docetaxel—skin cancer	0.000256	0.000635	CcSEcCtD
Atomoxetine—Headache—Fluorouracil—skin cancer	0.000256	0.000634	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000254	0.00063	CcSEcCtD
Atomoxetine—Fatigue—Docetaxel—skin cancer	0.000254	0.000629	CcSEcCtD
Atomoxetine—Constipation—Docetaxel—skin cancer	0.000252	0.000624	CcSEcCtD
Atomoxetine—Pain—Docetaxel—skin cancer	0.000252	0.000624	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—skin cancer	0.00025	0.314	CrCbGaD
Atomoxetine—Feeling abnormal—Docetaxel—skin cancer	0.000243	0.000602	CcSEcCtD
Atomoxetine—Nausea—Fluorouracil—skin cancer	0.000243	0.000601	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Docetaxel—skin cancer	0.000241	0.000597	CcSEcCtD
Atomoxetine—Body temperature increased—Docetaxel—skin cancer	0.000233	0.000577	CcSEcCtD
Atomoxetine—Abdominal pain—Docetaxel—skin cancer	0.000233	0.000577	CcSEcCtD
Atomoxetine—Asthenia—Docetaxel—skin cancer	0.000211	0.000524	CcSEcCtD
Atomoxetine—Pruritus—Docetaxel—skin cancer	0.000209	0.000517	CcSEcCtD
Atomoxetine—Diarrhoea—Docetaxel—skin cancer	0.000202	0.0005	CcSEcCtD
Atomoxetine—Dizziness—Docetaxel—skin cancer	0.000195	0.000483	CcSEcCtD
Atomoxetine—Vomiting—Docetaxel—skin cancer	0.000187	0.000464	CcSEcCtD
Atomoxetine—Rash—Docetaxel—skin cancer	0.000186	0.00046	CcSEcCtD
Atomoxetine—Dermatitis—Docetaxel—skin cancer	0.000186	0.00046	CcSEcCtD
Atomoxetine—Headache—Docetaxel—skin cancer	0.000185	0.000457	CcSEcCtD
Atomoxetine—Nausea—Docetaxel—skin cancer	0.000175	0.000434	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—skin cancer	0.000148	0.185	CrCbGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	9.85e-05	0.00478	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—MC1R—skin cancer	9.78e-05	0.00475	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	9.73e-05	0.00472	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—SMO—skin cancer	9.45e-05	0.00459	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PTCH1—skin cancer	9.45e-05	0.00459	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PTGER4—skin cancer	9.2e-05	0.00447	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTCH2—skin cancer	8.9e-05	0.00432	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.77e-05	0.00426	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	8.69e-05	0.00422	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GLI2—skin cancer	8.67e-05	0.00421	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RHOU—skin cancer	8.64e-05	0.00419	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	8.62e-05	0.00418	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RHOU—skin cancer	8.57e-05	0.00416	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	8.45e-05	0.0041	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	8.44e-05	0.0041	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RHOU—skin cancer	8.39e-05	0.00407	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MC1R—skin cancer	8.27e-05	0.00401	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GLI1—skin cancer	8.15e-05	0.00396	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	7.77e-05	0.00377	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SUFU—skin cancer	7.72e-05	0.00375	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	7.47e-05	0.00362	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—MC1R—skin cancer	7.41e-05	0.0036	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—SHH—skin cancer	7.17e-05	0.00348	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTCH2—skin cancer	7.14e-05	0.00347	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—SHH—skin cancer	7.11e-05	0.00345	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTCH2—skin cancer	7.09e-05	0.00344	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—SHH—skin cancer	6.97e-05	0.00338	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—CDK4—skin cancer	6.95e-05	0.00337	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTCH2—skin cancer	6.94e-05	0.00337	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—SMO—skin cancer	6.8e-05	0.0033	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—PTCH1—skin cancer	6.8e-05	0.0033	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—PTCH1—skin cancer	6.74e-05	0.00327	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—SMO—skin cancer	6.74e-05	0.00327	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—PTGER4—skin cancer	6.62e-05	0.00321	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—SMO—skin cancer	6.6e-05	0.00321	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—PTCH1—skin cancer	6.6e-05	0.00321	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—PTGER4—skin cancer	6.56e-05	0.00319	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	6.48e-05	0.00315	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—MC1R—skin cancer	6.43e-05	0.00312	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—PTGER4—skin cancer	6.43e-05	0.00312	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	6.4e-05	0.00311	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RHOU—skin cancer	6.36e-05	0.00309	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SHH—skin cancer	5.89e-05	0.00286	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	5.86e-05	0.00285	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RASA1—skin cancer	5.85e-05	0.00284	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—MC1R—skin cancer	5.69e-05	0.00276	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—MC1R—skin cancer	5.64e-05	0.00274	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SMO—skin cancer	5.58e-05	0.00271	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTCH1—skin cancer	5.58e-05	0.00271	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	5.56e-05	0.0027	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—MC1R—skin cancer	5.52e-05	0.00268	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RHOU—skin cancer	5.52e-05	0.00268	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTGER4—skin cancer	5.44e-05	0.00264	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—SHH—skin cancer	5.28e-05	0.00256	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTCH2—skin cancer	5.26e-05	0.00255	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MC1R—skin cancer	5.16e-05	0.00251	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MC1R—skin cancer	5.12e-05	0.00249	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MC1R—skin cancer	5.02e-05	0.00244	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—PTCH1—skin cancer	5e-05	0.00243	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—SMO—skin cancer	5e-05	0.00243	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—PTGER4—skin cancer	4.87e-05	0.00236	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—FOXO4—skin cancer	4.8e-05	0.00233	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	4.7e-05	0.00228	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—SHH—skin cancer	4.58e-05	0.00223	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTCH2—skin cancer	4.57e-05	0.00222	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.39e-05	0.00213	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—SMO—skin cancer	4.35e-05	0.00211	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTCH1—skin cancer	4.35e-05	0.00211	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTGER4—skin cancer	4.23e-05	0.00205	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTCH2—skin cancer	4.22e-05	0.00205	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—MC1R—skin cancer	4.19e-05	0.00203	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTCH2—skin cancer	4.19e-05	0.00203	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTCH2—skin cancer	4.1e-05	0.00199	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MC1R—skin cancer	3.8e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PTGER4—skin cancer	3.74e-05	0.00181	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PTGER4—skin cancer	3.71e-05	0.0018	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SHH—skin cancer	3.68e-05	0.00179	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SHH—skin cancer	3.65e-05	0.00177	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—MC1R—skin cancer	3.64e-05	0.00176	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PTGER4—skin cancer	3.63e-05	0.00176	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—BRAF—skin cancer	3.6e-05	0.00175	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SHH—skin cancer	3.57e-05	0.00174	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTCH1—skin cancer	3.49e-05	0.00169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SMO—skin cancer	3.49e-05	0.00169	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SMO—skin cancer	3.46e-05	0.00168	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTCH1—skin cancer	3.46e-05	0.00168	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTGER4—skin cancer	3.39e-05	0.00165	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SMO—skin cancer	3.39e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTCH1—skin cancer	3.39e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTGER4—skin cancer	3.37e-05	0.00164	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	3.31e-05	0.00161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MC1R—skin cancer	3.3e-05	0.0016	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTGER4—skin cancer	3.3e-05	0.0016	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TERT—skin cancer	3.21e-05	0.00156	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GLI2—skin cancer	3.2e-05	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GLI2—skin cancer	3.17e-05	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GLI2—skin cancer	3.11e-05	0.00151	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTCH2—skin cancer	3.11e-05	0.00151	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MC1R—skin cancer	3.05e-05	0.00148	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MC1R—skin cancer	3.03e-05	0.00147	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GLI1—skin cancer	3.01e-05	0.00146	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GLI1—skin cancer	2.98e-05	0.00145	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MC1R—skin cancer	2.96e-05	0.00144	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	2.95e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GLI1—skin cancer	2.92e-05	0.00142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SUFU—skin cancer	2.85e-05	0.00138	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SUFU—skin cancer	2.83e-05	0.00137	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SUFU—skin cancer	2.77e-05	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PTGER4—skin cancer	2.75e-05	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SHH—skin cancer	2.71e-05	0.00131	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	2.7e-05	0.00131	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—NRAS—skin cancer	2.7e-05	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTCH2—skin cancer	2.7e-05	0.00131	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTCH1—skin cancer	2.57e-05	0.00125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SMO—skin cancer	2.57e-05	0.00125	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BRAF—skin cancer	2.54e-05	0.00123	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.54e-05	0.00123	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTGER4—skin cancer	2.5e-05	0.00121	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PTGER4—skin cancer	2.39e-05	0.00116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GLI2—skin cancer	2.35e-05	0.00114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SHH—skin cancer	2.35e-05	0.00114	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—KRAS—skin cancer	2.33e-05	0.00113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MC1R—skin cancer	2.25e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTCH1—skin cancer	2.23e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SMO—skin cancer	2.23e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GLI1—skin cancer	2.21e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.2e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.18e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SHH—skin cancer	2.17e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTGER4—skin cancer	2.17e-05	0.00105	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	2.16e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RASA1—skin cancer	2.16e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SHH—skin cancer	2.16e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RASA1—skin cancer	2.14e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SHH—skin cancer	2.11e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SUFU—skin cancer	2.1e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RASA1—skin cancer	2.1e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMO—skin cancer	2.06e-05	0.001	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTCH1—skin cancer	2.06e-05	0.001	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTCH1—skin cancer	2.04e-05	0.000992	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GLI2—skin cancer	2.04e-05	0.000992	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMO—skin cancer	2.04e-05	0.000992	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTGER4—skin cancer	2.01e-05	0.000973	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTCH1—skin cancer	2e-05	0.000972	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMO—skin cancer	2e-05	0.000972	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	1.99e-05	0.000968	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTGER4—skin cancer	1.99e-05	0.000966	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HRAS—skin cancer	1.98e-05	0.00096	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLIN2—skin cancer	1.96e-05	0.000949	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MC1R—skin cancer	1.95e-05	0.000947	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTGER4—skin cancer	1.95e-05	0.000946	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GLI1—skin cancer	1.92e-05	0.000933	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.9e-05	0.00092	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—skin cancer	1.89e-05	0.000919	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.86e-05	0.000901	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SUFU—skin cancer	1.82e-05	0.000884	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLIN2—skin cancer	1.8e-05	0.000873	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.78e-05	0.000862	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FOXO4—skin cancer	1.77e-05	0.00086	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FOXO4—skin cancer	1.76e-05	0.000853	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FOXO4—skin cancer	1.72e-05	0.000836	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—HRAS—skin cancer	1.66e-05	0.000804	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.61e-05	0.000782	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SHH—skin cancer	1.6e-05	0.000777	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NRAS—skin cancer	1.6e-05	0.000775	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RASA1—skin cancer	1.59e-05	0.000772	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CSPG4—skin cancer	1.58e-05	0.000765	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.54e-05	0.000749	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTCH1—skin cancer	1.52e-05	0.000736	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMO—skin cancer	1.52e-05	0.000736	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTGER4—skin cancer	1.48e-05	0.000717	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CSPG4—skin cancer	1.45e-05	0.000704	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SHH—skin cancer	1.39e-05	0.000675	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RASA1—skin cancer	1.38e-05	0.00067	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—KRAS—skin cancer	1.37e-05	0.000667	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTCH1—skin cancer	1.32e-05	0.000639	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMO—skin cancer	1.32e-05	0.000639	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FOXO4—skin cancer	1.3e-05	0.000633	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTGER4—skin cancer	1.28e-05	0.000623	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—skin cancer	1.22e-05	0.000593	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TERT—skin cancer	1.18e-05	0.000574	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLIN2—skin cancer	1.18e-05	0.000571	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TERT—skin cancer	1.17e-05	0.00057	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—skin cancer	1.17e-05	0.000567	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TERT—skin cancer	1.15e-05	0.000558	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.13e-05	0.00055	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—skin cancer	1.12e-05	0.000543	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO2—skin cancer	1.07e-05	0.00052	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—NRAS—skin cancer	9.97e-06	0.000484	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—NRAS—skin cancer	9.89e-06	0.00048	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO2—skin cancer	9.85e-06	0.000478	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—NRAS—skin cancer	9.69e-06	0.00047	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CSPG4—skin cancer	9.48e-06	0.00046	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—skin cancer	9.37e-06	0.000455	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—skin cancer	9.3e-06	0.000451	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—skin cancer	9.11e-06	0.000442	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—skin cancer	8.71e-06	0.000423	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—skin cancer	8.58e-06	0.000416	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—skin cancer	8.51e-06	0.000413	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.38e-06	0.000407	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—skin cancer	8.34e-06	0.000405	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—skin cancer	7.57e-06	0.000367	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—skin cancer	7.34e-06	0.000356	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—skin cancer	7.29e-06	0.000354	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—skin cancer	7.24e-06	0.000351	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—skin cancer	7.09e-06	0.000344	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—skin cancer	6.98e-06	0.000339	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—skin cancer	6.93e-06	0.000336	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—skin cancer	6.9e-06	0.000335	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—skin cancer	6.78e-06	0.000329	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—skin cancer	6.44e-06	0.000313	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—skin cancer	6.37e-06	0.000309	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—skin cancer	6.32e-06	0.000307	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ERCC2—skin cancer	6.22e-06	0.000302	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—skin cancer	5.99e-06	0.000291	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—skin cancer	5.89e-06	0.000286	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—skin cancer	5.84e-06	0.000284	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ERCC2—skin cancer	5.72e-06	0.000278	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—skin cancer	5.72e-06	0.000278	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—skin cancer	5.49e-06	0.000266	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—skin cancer	5.37e-06	0.000261	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—skin cancer	5.14e-06	0.00025	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—skin cancer	5.07e-06	0.000246	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—skin cancer	5.03e-06	0.000244	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—skin cancer	4.93e-06	0.000239	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—skin cancer	4.66e-06	0.000226	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—skin cancer	4.5e-06	0.000219	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—skin cancer	4.47e-06	0.000217	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—skin cancer	4.46e-06	0.000217	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—skin cancer	4.38e-06	0.000212	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—skin cancer	4.34e-06	0.000211	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—skin cancer	4.31e-06	0.000209	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—skin cancer	4.28e-06	0.000208	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—skin cancer	4.19e-06	0.000203	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—skin cancer	4.12e-06	0.0002	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—skin cancer	4.09e-06	0.000199	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—skin cancer	4.01e-06	0.000194	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—skin cancer	3.77e-06	0.000183	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ERCC2—skin cancer	3.74e-06	0.000182	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—skin cancer	3.73e-06	0.000181	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—skin cancer	3.73e-06	0.000181	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—skin cancer	3.43e-06	0.000167	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—skin cancer	3.32e-06	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—skin cancer	3.24e-06	0.000157	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—skin cancer	3.17e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—skin cancer	3.04e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—skin cancer	2.88e-06	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—skin cancer	2.76e-06	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—skin cancer	2.64e-06	0.000128	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—skin cancer	2.24e-06	0.000109	CbGpPWpGaD
